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Abstract
Herpesvirus entry is a complicated process involving multiple virion glycoproteins and culminating in membrane fusion.
Glycoprotein conformation changes are likely to play key roles. Studies of recombinant glycoproteins have revealed some
structural features of the virion fusion machinery. However, how the virion glycoproteins change during infection remains
unclear. Here using conformation-specific monoclonal antibodies we show in situ that each component of the Murid
Herpesvirus-4 (MuHV-4) entry machinery—gB, gH/gL and gp150—changes in antigenicity before tegument protein release
begins. Further changes then occurred upon actual membrane fusion. Thus virions revealed their final fusogenic form only
in late endosomes. The substantial antigenic differences between this form and that of extracellular virions suggested that
antibodies have only a limited opportunity to block virion membrane fusion.
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Introduction
Enveloped viruses penetrate cells by membrane fusion. Her-
pesvirus fusion requires gB and gH, which forms a heterodimer
with gL [1]. A directly fusogenic role for gB is implied by its
structural homology to the Vesicular stomatitis virus glycoprotein
G (VSV-G) [2,3]. gH/gL does not appear to be a typical fusogen
[4], but has a conserved hydrophobic patch that could participate
in fusion [5]. An additional virion glycoprotein often regulates
gH/gL/gB. For example the Herpes simplex virus (HSV) gD
brings together gH/gL and gB in transfected cells after receptor
binding [6–8], although how this works is still debated.
Membrane fusion is driven by conformation changes in virion
glycoproteins [9,10]. The rationale for pre-fusion glycoprotein
changes such as that of the HSV gD [6] is less clear. One possi-
bility is antibody evasion, and a post-binding conformation change
in the HIV gp120 has been proposed to limit the exposure to
antibody of its functionally important epitopes [11]. However gD
remains a prominent neutralization target for HSV despite its
change [12], and although low pH induces changes in the post-
fusion HSV gB [13] pre-fusion changes have not been identified in
either gB or gH/gL.
A full understanding of herpesvirus membrane fusion may
require analysis beyond HSV. Murid Herpesvirus-4 (MuHV-4)
provides an accessible way to study gamma-herpesvirus infection
[14,15]. Like other mammalian herpesviruses, it encodes homo-
logs of gH and gB that are essential for infectivity [16]. MuHV-4
infects epithelial cells by first binding to heparan sulfate (HS) via
gp70 [17] or gH/gL [18]. Virions are then endocytosed and show
pH-dependent capsid release from late endosomes [19]. Confor-
mation-dependent monoclonal antibodies (mAbs) have identified
antigenic changes in gB and gH that broadly coincide with
membrane fusion. Thus extracellular virion gB (by definition pre-
fusion) is recognized by mAb BN-1A7 but not by mAb MG-1A12
(BN-1A7
+MG-1A12
-), whereas after capsid release from late
endosomes gB (now by definition post-fusion) is BN-1A7
-MG-
1A12
+ [20]. Similarly while extracellular virions have gH mostly
bound to gL [21], late endosomal virions lose gL-dependent
epitopes (gH/gL) and retain gL-independent epitopes (gH-only),
implying gH/gL dissociation or an analogous conformation
change [22]. However, whether these changes are part of the
fusion reaction or simply associated with it has been unclear.
Not all the gH and gB on herpes virions need necessarily be
engaged for membrane fusion to occur. Nevertheless the
engagement of one glycoprotein complex presumably lowers the
threshold for subsequent engagements, and the fraction of the
available glycoproteins on enveloped virions that engage in fusion
seems to be high [10]. Thus the fusogenic role of gB and the
coincidence of its antigenic switch with capsid release argue that
this reflects a fusion-associated conformation change. The
situation for gH is less clear: a constitutive association with gB
[23] would suggest that it undergoes inter-dependent conforma-
tion changes, but gL is non-essential for infection [24], implying
that gH/gL epitope loss is not intrinsic to the fusion reaction.
Gp150 is another component of the MuHV-4 entry complex
[23]. Like gL it is non-essential for infectivity; indeed gp150
-
virions are more infectious than the wild-type, in that they are less
HS-dependent [25,26]. Thus gp150 regulates HS-independent cell
binding. The gp150 homologs of EBV (gp350) and BoHV-4
(gp180) also have regulatory functions: gp180
- BoHV-4 shows
enhanced infection of HS-deficient cells [27], and gp350
- EBV
shows enhanced infection of epithelial cells [28]. Each of these
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30152Figure 1. Kinetic analysis of antigenic changes in gB. (A) NMuMG cells were incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and then
either fixed immediately or first further incubated (1h and 2h, 37uC) to allow virion endocytosis. The cells were then stained with the gB-specific mAbs
BN-1A7 and MG-1A12 (green). BN-1A7 (IgG2a) recognizes only pre-fusion gB; MG-1A12 (IgG2a) recognizes a gB epitope that is inaccessible on
extracellular virions but becomes accessible after endocytosis. The cells were also stained for LAMP-1 (red) and counter-stained with DAPI (blue). (B)
NMuMG cells were incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and then either fixed immediately or first further incubated (1h, 37uC) to
allow virion endocytosis. The cells were then co-stained with the gB-specific mAbs SC-9A5 (IgG3, green) and MG-1A12 (IgG2a, red). SC-9A5 recognizes
only pre-fusion gB. The arrow points to a gB focus in the extracellular SC-9A5
+MG-1A12
- antigenic state; the arrowhead points to a focus of gB that is
both SC-9A5
+ and MG-1A12
+. (C) NMuMG cells were incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and fixed after a further incubation to
allow virion endocytosis (30 min, 37uC). The cells were then stained with the gB-specific IgG2a MG-1A12 (green) and for EEA-1 (red), and counter-
stained with DAPI (blue). (D) The cells were infected and processed as in (C) but stained with the gB-specific IgG2a BN-1A7 (green). In this and all
subsequent figures, the data shown are representative of at least 100 cells examined. Note that MuHV-4 plaque titers underestimate virion numbers
10-100 fold.
doi:10.1371/journal.pone.0030152.g001
Figure 2. Kinetic analysis of antigenic changes in gH. (A) NMuMG cells were incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and then
either fixed immediately or first further incubated (1h and 2h, 37uC) to allow virion endocytosis. The cells were then stained with the gH-specific
mAbs T2C12 and MG-9B10 (green). T2C12 (IgG2a) recognizes only gH complexed with gL (gH/gL); MG-9B10 (IgG2a) recognizes only gH which is not
associated with gL (gH-only). The cells were also stained for LAMP-1 (red) and counter-stained with DAPI (blue). (B) Cells were infected and processed
as in (A). Infected cells and uninfected control cells were then incubated with the gB-specific mAbs BN-1A7 (IgG2a) and MG-1A12 (IgG2a), the gH/gL-
specific mAb T2C12 (IgG2a) and the gH-only-specific mAb MG-9B10 (IgG2a). Bound antibody was detected with an alkaline phosphatase-conjugated
secondary antibody and incubation with p-nitrophenyl phosphate substrate. The bars show mean 6 SEM values from 6 wells. The experiment shown
is representative of two equivalent experiments.
doi:10.1371/journal.pone.0030152.g002
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entry to relieve its inhibitory effect. However corresponding
antigenic changes have not been identified. Here we show that the
MuHV-4 gB, gH and gp150 all undergo antigenic changes
upstream of membrane fusion, with different blocks to membrane
fusion arresting virions in different intermediate states. Thus the
entry complex engaging in fusion was substantially different to that
displayed on extracellular virions. Since MuHV-4 infection is
endocytic this may substantially protect the fusogenic form against
extracellular antibodies.
Results
Two distinct antigenic changes in gB
The glycoprotein conformations of cell-bound, non-endocy-
tosed virions must be pre-fusion; after capsid release from late
endosomes they must at least in part be post-fusion. Between cell
binding and capsid release MuHV-4 virions lose gH/gL epitopes,
while gB switches from BN-1A7
+MG-1A12
- to BN-1A7
-MG-
1A12
+. To define better the relationship between these antigenic
switches, we undertook a kinetic analysis of virion entry, binding
virions to cells at 4uC, then incubating them for different times at
37uC to allow endocytosis and observing how their antigenicity
changed (Fig. 1).
We first analysed gB (Fig. 1A). After cell binding at 4uC, virions
were detected by mAb BN-1A7 but not by mAb MG-1A12. After
a1 h3 7 uC incubation, virions were detected by both mAbs in late
endosomes, based on co-localization with LAMP-1. After 2h at
37uC, virions were detected with mAb MG-1A12 but not with
BN-1A7. Therefore MG-1A12 epitope gain preceded BN-1A7
epitope loss.
Endocytic MuHV-4 transport is not completely synchronous,
and glycoprotein antigenicity correlates principally with virion site
- whether inside or outside late endosomes [20,22]. Thus at the
intermediate 1h timepoint the BN-1A7
+ and MG-1A12
+ virions
were possibly distinct populations at different stages of infection.
To compare them more directly we used mAb SC-9A5, which like
BN-1A7 recognizes gB only before capsid release [29] but is IgG3
and so allows isotype-specific co-staining with MG-1A12 (IgG2a).
After 1h at 37uC. SC-9A5
+ and MG-1A12
+ virions co-localized in
individual endosomes (Fig. 1B). Therefore virions in the same
intracellular site expressed a gB epitope present post- but not pre-
fusion (MG-1A12), and one present pre- but not post-fusion (SC-
9A5). The co-existence of these epitopes suggested that gB might
have an additional intermediate state that was neither stably pre-
fusion nor post-fusion.
MG-1A12 staining also appeared very early (30 min) after switching
cell-bound virions to 37uC (Fig. 1C). At this time it overlapped in
localization with the early endosome marker EEA-1, as did BN-1A7
staining (Fig. 1D). Thus virions adopted the BN-1A7
+MG-1A12
+
intermediate state before they reached late endosomes.
gH also shows distinct antigenic changes
After 2h at 4uC, cell-bound virions were detected by both mAb
T2C12 (gH/gL) and mAb MG-9B10 (gH-only), but after a further
1h at 37uC these mAbs showed distinct staining patterns (Fig. 2A).
gH-only staining, like that of gB showed co-localization with
LAMP-1; in contrast, gH/gL staining was reduced and the
residual staining was peri-nuclear with little or no LAMP-1 co-
localization. After 2h at 37uC neither mAb co-localized with
LAMP-1. Thus again virions appeared to pass through two distinct
stages: loss/redistribution of gH/gL, then loss/redistribution of
gH-only.
Virion antigenic changes measured by ELISA
We used ELISA to quantitate the antigenic changes in gB and
gH/gL across cell populations (Fig. 2B). Infection conditions were
the same as for immunofluorescence, but after cell fixation and
permeabilization we detected antibody binding with an alkaline
phosphatase-conjugated secondary antibody and a soluble,
colorimetric substrate. Fig. S1 shows corresponding immunoflu-
orescence images. The different assay results correlated well for
gB: first the MG-1A12 epitope appeared, then the BN-1A7
epitope was lost. However the gH-only signal remained surpris-
ingly constant after 2h at 37uC. Thus gH-only appeared to be
more redistributed from late endosomes than lost. gH/gL
detection by mAb T2C12 was reduced by incubation at 37uC
but less markedly than that of gB detection by mAb BN-1A7.
Again this would be consistent with the lack of late endosomal gH/
gL being partly due to redistribution. A similar lack of late
endosomal gH/gL by immunofluorescence and partial loss by
ELISA was seen with mAb 7E5, which recognizes a distinct gH/
gL epitope [21] (Fig. S2).
High endosomal pH and gB-directed neutralization arrest
the virion fusion complex in different intermediate states
Raising the endosomal pH of virus-exposed cells with con-
canamycin A (ConA) prevents MuHV-4 infection and keeps gB in
its pre-fusion state - BN-1A7
+MG-1A12
- [20,22] (Fig. 3). In
contrast, raising the endosomal pH with ammonium chloride
(NH4Cl) blocked BN-1A7 epitope loss without preventing MG-
1A12 epitope display, as did blocking membrane fusion with the
gB-specific neutralizing mAb SC-9A5 [29] (Fig. 3). None of these
treatments affected endocytic virion transport or staining by a pan-
gB-specific mAb, MG-4D11 (Fig. S3). Thus NH4Cl and SC-9A5
treatments stably arrested gB in LAMP-1
+ late endosomes in its
intermediate BN-1A7
+MG-1A12
+ state.
We examined the same inhibitors for their effect on gH (Fig. 4).
Again virions were bound to cells at 4uC, then incubated at 37uC
to allow endocytosis. ConA and NH4Cl treatments blocked gH/gL
epitope loss/redistribution, while mAb SC-9A5 did not (Fig. 4A).
All 3 treatments blocked gH-only epitope loss/redistribution
(Fig. 4B). Thus ConA kept virions in their extracellular form
(gH/gL
+BN-1A7
+MG-1A12
-); NH4Cl preserved gH/gL in late
endosomes but kept gB as BN-1A7
+MG-1A12
+; and SC-9A5 had
the same effect on gB but arrested gH as gH-only rather than as
gH/gL. Fig. 5A summarizes these 3 different blocks.
Figure 5B shows how much each block inhibited tegument
protein release. The abundant tegument protein encoded by
Figure 3. Concanamycin A and NH4Cl treatments and virus neutralization by mAb SC-9A5 arrest gB in distinct antigenic states.
MuHV-4 (3 p.f.u./cell) was left untreated (nil) or pre-incubated (2h, 37uC) with 400 mg/ml SC-9A5 (IgG3) before binding to NMuMG cells (2h, 4uC). For
drug treatments, cells were incubated with 1 mM concanamycin A and 25 mM NH4Cl before adding virus (2h, 37uC) and during binding (2h, 4uC).
Unbound virions were then removed by washing and the cells either fixed immediately or after a further incubation (2h, 37uC) in presence or absence
of antibodies and drugs. In (A) the cells were stained with the gB-specific IgG2a BN-1A7 and in (B) with the gB-specific IgG2a MG-1A12 (green). The
cells were also stained for LAMP-1 (red) and with DAPI (blue). Treating cells with DMSO alone had no effect (not shown). Treatment of cells with
concanamycin A arrests gB in its extracellular BN-1A7
+MG-1A12
- form, while treatment with NH4Cl and virus neutralization by SC-9A5 arrest gB at an
intermediate BN-1A7
+MG-1A12
+ state.
doi:10.1371/journal.pone.0030152.g003
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30152Figure 4. gH undergoes pre-fusion and fusion-related antigenic changes. Infections, drug treatments and antibody treatments were as for
Figure 3. In (A) the cells were stained with the gH/gL-specific IgG2a T2C12 and in (B) with the gH-only-specific IgG2a MG-9B10 (green). The cells were
also stained for LAMP-1 (red) and with DAPI (blue). Treating cells with DMSO alone had no effect (not shown).
doi:10.1371/journal.pone.0030152.g004
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and so provides a useful marker of virion membrane fusion.
ORF75c staining also shows a marked increase in intensity after
fusion, presumably because protein confined within the virion
tegument is poorly accessible to antibody [29]. NH4Cl and SC-
9A5 treatments blocked ORF75c release at least as effectively as
did ConA (Fig. 5B), and each was effective for at least 6h (Fig. S4).
Therefore the entry blocks by ConA, NH4Cl and SC-9A5 were
qualitatively rather than just quantitatively distinct, and the
inhibitions of glycoprotein conformations (Fig. 3, Fig. 4) correlated
with the inhibition of tegument protein release (Fig. 5).
Pre-fusion antigenic changes in gp150
Since gp150 is also part of the MuHV-4 entry complex [23], we
looked to see whether it too showed entry-associated antigenic
changes. We used mAbs that recognize epitopes in the N-terminal
(amino acid residues 1-150, mAb BN-3A4), central (residues 150-
250, mAb T1A1) or C-terminal (residues 301-450, mAb BH-6H2)
regions of the gp150 extracellular domain. All these mAbs
recognized linear epitopes (Fig. S5). BN-3A4 recognition was
further mapped by ELISA to a 15-mer peptide ETEPESPTPL-
PATPK, corresponding to gp150 residues 127-141 (data not
shown). As before we bound virions to cells at 4uC, and then either
fixed and stained them immediately or first incubated them at
37uC to allow endocytosis. Each mAb recognized virions bound to
the plasma membrane (Fig. 6A, 6B). After 1h at 37uC, recognition
by BN-3A4 and T1A1 (Fig. 6A) was greatly reduced while
recognition by BH-6H2 (Fig. 6B) was retained. Some redistribu-
tion of BH-6H2 staining was evident, particularly after 2h at 37uC.
Signal quantitation by ELISA (Fig. 6C) confirmed these results.
Although the loss of staining by BN-3A4 and T1A1 was a loss of
linear epitope recognition, immunoblots (Fig. 6D) showed no sign
of gp150 degradation. Therefore 2 epitopes in distinct regions of
the gp150 extracellular domain became hidden by rearrange-
ment/conformation changes of the virion fusion complex. ConA
and NH4Cl preserved gp150 recognition by T1A1 (Fig. 7A) and
BN-3A4 (Fig. S6). Therefore these changes were pH-dependent.
MAb SC-9A5, which blocked membrane fusion, did not prevent
T1A1 and BN-3A4 epitope loss. Therefore these changes were
also pre-fusion. In contrast all 3 treatments blocked the
redistribution of BH-6H2 staining (Fig. 7B). Therefore this seemed
to reflect membrane fusion.
The fusion complex changes are not simply pH-
dependent
Low pH is a well-established trigger of glycoprotein conforma-
tion changes for endocytic viruses [10], and the antigenic changes
in MuHV-4 glycoproteins required low endosomal pH. However,
when virions were bound to ELISA plates and exposed to low pH
here rather than in endosomes (Fig. 8), the only marked effect was
to increase MG-1A12 recognition. This was surprising, as while
MG-1A12 epitope display was blocked by ConA treatment, it was
not blocked by NH4Cl. The likely explanation is that MG-1A12
epitope display requires only a small pH drop - 10mM NH4Cl
would still allow the endosomal pH to reach 6.5 [31]. This would
be consistent with its appearance in early endosomes (Fig. 1C).
That low pH alone was insufficient to drive the other MuHV-4
antigenic changes implied that receptor binding and other aspects
of the endosomal milieu might also play important roles.
Independence and inter-dependence in the changes to
gH and gp150
The correlation across different inhibitor treatments of ORF75c
release, BN-1A7
+ gB loss, and MG-9B10
+ gH and BH-6H2
+
gp150 redistributions, argued that these are all aspects of a
common fusion event. In contrast, the pre-fusion changes in gH
and gB - gH/gL epitope loss and MG-1A12 epitope gain - showed
at least partial independence: NH4Cl treatment established that
gH/gL loss was unnecessary for MG-1A12 gain, and that MG-
1A12 gain was insufficient for gH/gL loss. We used knockout
viruses to look for inter-dependence of the pre-fusion changes in
gH/gL and gp150 (Fig. 9). Again we bound virions to cells at 4uC
then incubated at 37uC to allow endocytosis, but compared wild-
type virions with those lacking either gp150 (BN-3A4
-T1A1
-BH-
6H2
-) or gL (gH/gL
-gH-only
+). Gp150
- virions showed the same
gH and gB changes as wild-type (Fig. 9A). Therefore gp150 did
not hide the MG-1A12 epitope or obviously affect gH/gL. gL
-
virions also displayed each gp150 epitope, so gH/gL dissociation
was not responsible for gp150 epitope loss (or for MG-1A12
epitope gain). gL
- virions are poorly transported to late endosomes
[22]. Thus even after 2h at 37uC they remained largely BN-
1A7
+MG-1A12
- (no pre-fusion change in gB) and T1A1
+ (no pre-
fusion change in gp150) (Fig. 9B). They also remained BN-3A4
+
(data not shown). Therefore bar a common requirement for virion
endocytosis and low pH, the pre-fusion changes in gH, gB and
gp150 showed substantial independence.
Discussion
MuHV-4 virions show multiple glycoprotein antigenic changes
as they enter epithelial cells. Inhibitors of membrane fusion
identified gB MG-1A12 epitope gain, gp150 BN-3A4 and T1A1
epitope loss and gH/gL epitope loss as pre-fusion events. Each
required low pH, but low pH alone triggered only the change in
gB. Therefore other aspects of the endosomal milieu were required
to change gH/gL and gp150. All these changes depended on
virion endocytosis, and the antigenic switching between virions at
the cell surface and those engaging in fusion in late endosomes
presumably helps MuHV-4 to evade antibody-mediated neutral-
ization.
An important question is what structural/organizational
changes in the virion fusion complex the antigenic changes
represent. The MG-1A12 epitope on gB was not hidden by gH/gL
or gp150, as it was revealed before their antigenicity changed, and
was not revealed when virions lacked gp150 or gL. It presumably
reflected instead a change in gB itself. Another gB antigenic
change - BN-1A7 epitope loss - then occurred upon fusion. Thus
Figure 5. gH and gB antigenic changes during virus entry and the effect of drug treatments and antibody-mediated neutralization
on ORF75c tegument protein release. (A) A schematic diagram summarizes the progress of antigenic changes in gH and gB during virion entry,
and the distinct blocks to this progresses effected by concanamycin A (ConA), NH4Cl, and antibody-mediated neutralization by SC-9A5. gH/gL
epitopes are lost upstream of fusion, while gH-only epitopes are lost/redistributed upon membrane fusion. The MG-1A12 gB epitope is revealed
upstream of fusion, while the BN-1A7 epitope disappears upon fusion. Both NH4Cl treatment and virus neutralization by mAb SC-9A5 arrest gB in an
intermediate BN-1A7
+MG-1A12
+ state. (B) Infections, drug treatments and antibody treatments were as for Figure 3. The cells were stained with the
ORF75c-specific IgG1 BN-8C3 (green), a LAMP-1-specific mAb (red), and DAPI (blue). All images were taken with the same confocal settings.
Incubating cells with DMSO alone had no effect (not shown). Concanamycin A and NH4Cl treatments and virus neutralization by SC-9A5 all inhibit
viral membrane fusion and ORF75c tegument protein release.
doi:10.1371/journal.pone.0030152.g005
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1A7
+MG-1A12
- to BN-1A7
+MG-1A12
+ to BN-1A7
-MG-1A12
+),
or the switch to BN-1A7
+MG-1A12
+ could reflect a reversible
equilibrium being established between BN-1A7
+MG-1A12
- (pre-
fusion) and BN-1A7
-MG-1A12
+ (post-fusion) gB, as described for
VSV-G [10]. An irreversible switch to post-fusion would then be
driven by membrane binding [29]. Existing structural data cannot
resolve these possibilities, as only post-fusion gB has been
identified. Low pH induces local changes in the post-fusion
HSV gB [13], but this has uncertain functional significance as
HSV fusion is classically pH-independent [32]; different changes
may occur in other recombinant forms of HSV gB [33] but remain
structurally uncharacterized.
Fusion-associated changes were less clear for gH and gp150.
This was unsurprising for gp150, as it probably does not
participate directly in fusion. However, fusion does require gH.
The MuHV-4 gH can be either gH/gL or gH-only. gL is non-
essential for infectivity, and virions reaching their fusion site (late
endosomes) lost gH/gL epitopes even when mAb SC-9A5 blocked
fusion. Therefore fusion involves gH-only rather than gH/gL, and
the gH/gL of extracellular virions [23] must change to gH-only
before fusion occurs. That other herpesviruses require gL to
process gH [34] and incorporate it into virions [35,36] does not
exclude that they follow a similar scheme.
The MuHV-4 gH/gL binds to HS [18]; it may also deliver a pro-
endocytic signal, as a major phenotype of gL
- virions is poor
transport to late endosomes. Late endosomal gH/gL loss must
therefore reduce cell binding. Gp150 regulates HS-independent cell
binding, and the late endosomal loss of BN-3A4 and T1A1 epitopes
could have reflected gp150 displacement for a compensatory
increase in HS-independent cell binding. If gH-only engages
directly in membrane fusion, another gH conformation change
might be expected, as with gB (BN-1A7 epitope loss), and the
immunofluorescence data did suggest that gH-only epitopes are lost
when fusion occurs. However the ELISA data argued that fusion
mainly dilutes gH-only by allowing its redistribution. Therefore it
remains possible that gH-only simply licences fusion by gB.
We know that gL protects MuHV-4 against neutralization by
gH-only-specific antibodies [37], and that BN-1A7
+MG-1A12
+ gB
was inaccessible on extracellular virions could explain the difficulty
[19] of gB-directed MuHV-4 neutralization. MAb SC-9A5
neutralizes well, but its epitope is rarely recognized by MuHV-
4-infected or gB-vaccinated mice [38], suggesting that it is hard to
reach. Gp150 seems not to be a significant neutralization target
[39]. Thus the post-endocytic reorganization of gH, gB and gp150
makes sense as a mechanism of viral antibody evasion.
Materials and Methods
Cells
NMuMG epithelial cells (American Type Culture Collection
CRL-1636), BHK-21 fibroblasts (CCL-10), and 293T cells (CRL-
11268) were grown in Dulbecco’s Modified Eagle’s Medium with
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin
and 10% fetal calf serum (complete medium).
Plasmids
N-terminal fragments (amino acid residues 1-150, 1-250 and 1-
450) of the gp150 coding sequence (genomic co-ordinates 69466-
70917) [40] were amplified by PCR (Hi-Fidelity PCR kit, Roche
Diagnostics Ltd) using 59 XbaI-restricted and 39 NotI-restricted
primers, and cloned into the XbaI/NotI sites of pBRAD, thereby
attaching a C-terminal glycosyl-phosphatidyl-inositol (GPI) mem-
brane anchor [41]. The 301-450 amino acid residue fragment was
amplified instead with a SmaI-restricted 59 primer, then cloned as a
SmaI/NotI fragment into the equivalent sites of pBRAD-gp150 (1-
150). This removed gp150 residues 31-150 from the original
plasmid and joined residue 29 to residue 301 via a SmaI restriction
site. The predicted gp150 signal sequence cleavage site lies
between residues 22 and 23. Thus this construct retained the 7
residues after the signal sequence cleavage site then encoded
residues 301-450. Each construct was transfected into 293T cells
using Fugene-6 (Roche Diagnostics Ltd).
Viruses
All viruses were derived from a MuHV-4 BAC [42]. gL
- [24]
and gp150
- mutants [25] have been described. The loxP-flanked
BAC cassette was removed from viral genomes by passage through
NIH-3T3-CRE cells [25]. Virus stocks were grown in BHK-21
cells [25]. Cell debris was removed by low speed centrifugation
(1000 x g, 10 min) and virions were recovered from supernatants
by high speed centrifugation (38,000 x g, 90 min). Virus stocks
were titrated by plaque assay [25]. After incubation with virus (2h,
37uC), BHK-21 cell monolayers were overlaid with 0.3%
carboxymethylcellulose and 4 days later fixed with 4% formalde-
hyde and stained with 0.1% toluidine blue.
Antibodies
MuHV-4-specific mAbs were derived from MuHV-4-infected
BALB/c mice. All animal experiments were approved by the
Cambridge University ethical review board and by the UK Home
Office (PPL 80/1992). Staining was with hybridoma supernatants.
For virus neutralization with mAb SC-9A5, hybridoma superna-
tant was concentrated by ammonium sulfate precipitation,
dialysed against PBS, and quantitated by Mancini assay [43].
Rat anti-mouse LAMP-1 mAb (clone 1D4B) was from BD
Biosciences, rabbit anti-EEA-1 polyclonal antibody (pAb) from
Abcam, and mouse anti-actin mAb (clone AC-40) from Sigma-
Aldrich.
Drug treatments
Concanamycin A (Sigma-Aldrich) stock solutions were prepared
at 150 mM in DMSO. Treatment with identical volumes of
DMSO served as a negative control. Ammonium chloride stock
solution was prepared at 2M in H2O. Cells were treated for 2h at
Figure 6. Antigenic changes in gp150 during virus entry. (A) NMuMG cells were incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and
then either fixed immediately or first further incubated (1h and 2h, 37uC) to allow virion endocytosis. The cells were then stained with the gp150-
specific mAbs BN-3A4 and T1A1 (green). BN-3A4 (IgG1) recognizes an epitope in the gp150 N-terminal (amino acid residues 1-150), T1A1 (IgG2a)a n
epitope in the central (residues 150-250). (B) Cells were infected and processed as in (A) but stained with mAb BH-6H2 (IgG2b), which recognises an
epitope in the gp150 C-terminal (residues 301-450) extracellular domain. (C) Cells were infected and processed as in (A). Infected cells and
uninfected control cells were then incubated with the gp150-specific mAbs BN-3A4 (IgG1), T1A1 (IgG2a), and BH-6H2 (IgG2b). Bound antibody was
detected with alkaline phosphatase-conjugated secondary antibodies and incubation with p-nitrophenyl phosphate substrate. The bars show mean
6 SEM values from 6 wells. The experiment shown is representative of two equivalent experiments. (D) Cells were infected and processed as in (A).
Lysates of infected cells and uninfected control cells were then analyzed by immunoblot with the gp150-specific mAbs BN-3A4 (IgG1), T1A1 (IgG2a),
and BH-6H2 (IgG2b). Detection of actin served as loading control.
doi:10.1371/journal.pone.0030152.g006
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during virus endocytosis at 37uC.
Immunofluorescence
NMuMG cells were seeded overnight onto glass cover-slips.
MuHV-4 virions (3 p.f.u./cell) were bound to the cells (2h, 4uC).
The cells were then washed x3 in ice-cold PBS to remove unbound
virions, and either fixed or first incubated for the indicated time at
37uC in complete medium with or without drugs and antibodies.
After one wash in ice-cold PBS, fixation was achieved by adding
ice-cold 4% formaldehyde in PBS and leaving at room
temperature (RT) for 30 min (mAb BN-8C3) or 1h (all other
mAbs). Fixation was stopped by adding 0.1M glycine (15 min,
RT), followed by 3 washes in PBS. The cells were then
permeabilized with 0.1% Triton X-100 (30 min, RT), blocked
with 2% bovine serum albumin 0.1% Tween-20 (overnight, 4uC),
stained with primary mAbs (1h, RT), washed x3 in PBS 0.1%
Tween-20, stained with secondary antibodies with 1 mg/ml DAPI
(1h, RT), washed x3 in PBS 0.1% Tween-20 and x1 in H2O, and
mounted in ProLong Gold (Invitrogen). Secondary antibodies
(goat anti-rat IgG, goat anti-rabbit IgG, and goat anti-mouse IgG,
IgG1, IgG2a, IgG2b or IgG3, labeled with Alexa Fluor 488 or 568)
were all from Invitrogen. Images were acquired on Leica TCS SP2
and SP5 AOBS confocal laser scanning microscopes with settings
specific for DAPI (excitation 405 nm, recording 410–470 nm),
Alexa Fluor 488 (excitation 488 nm, recording 493-550 nm), and
Alexa Fluor 568 (excitation 561 nm, recording 566–700 nm).
Images were analyzed with ImageJ.
Immunoblotting
Cells or virions were lysed and denatured by heating in
Laemmli’s buffer (95uC, 5 min for virions and 15 min for cells).
Proteins were resolved by SDS-PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes (Millipore). The
membranes were blocked for 1h at RT with 5% skim milk in PBS-
T (PBS + 0.3% Tween-20) and probed with MuHV-4-specific
mAbs diluted in 2.5% skim milk in PBS-T (1h, RT), followed by 4
washes in PBS-T. The membranes were then incubated with
horseradish peroxidase-conjugated rabbit anti-mouse Ig pAb
(DakoCytomation) diluted in 2.5% skimmed milk in PBS-T (1 h,
RT), followed by 4 washes in PBS-T and 1 wash in PBS. Bound
secondary antibody was detected with Amersham ECL Western
blotting detection reagent (GE Healthcare), followed by exposure
to X-ray films (Fuji).
Flow cytometry
Transfected or MuHV-4-infected cells were trypsinized and
washed in PBS. Cells were then incubated (1 h, 4uC) with MuHV-
4 glycoprotein-specific mAbs followed by fluorescein-conjugated
rabbit anti-mouse IgG pAb (Dako Cytomation) diluted in 5%
rabbit serum. All samples were washed x2 in PBS and analyzed on
a FACSCalibur (BD Biosciences).
Cell ELISA
NMuMG cells were seeded overnight into 96-well plates.
MuHV-4 virions (3 p.f.u./cell) were bound to the cells (2h, 4uC).
The cells were then washed x3 in ice-cold PBS to remove unbound
virions, and either fixed directly or first incubated at 37uCi n
Figure 7. Gp150 undergoes pre-fusion antigenic changes. Infections, drug treatments and antibody treatments were as for Figure 3. In (A)
the cells were stained with the gp150-specific IgG2a BN-3A4, in (B) with the gp150-specific IgG2a T1A1 (green), and in (C) with the gp150-specific
IgG2b BH-6H2. The cells were also stained for LAMP-1 (red) and with DAPI (blue). Treating cells with DMSO alone had no effect (not shown).
doi:10.1371/journal.pone.0030152.g007
Figure 8. Exposing virions to low pH reveals the gB MG-1A12 epitope, but fails to trigger antigenic changes in gH and gp150. Virions
(10
5 p.f.u./well) were absorbed to 96-well ELISA plates at neutral pH (overnight, 4uC). After washing to remove unbound virions, the plates were
treated with phosphate-citrate buffers with pH 7, 6, 5, and 4 (15 min, 37uC). Virions were then probed with gB-specific mAbs BN-1A7 (IgG2a) and MG-
1A12 (IgG2a), gH/gL-specific mAbs T2C12 (IgG2a) and 7E5 (IgG2a), the gH-only-specific mAb MG-9B10 (IgG2a), and gp150-specific mAbs BN-3A4 (IgG1),
T1A1 (IgG2a) and BH-6H2 (IgG2b). Bound antibody was detected with an alkaline phosphatase-conjugated secondary antibody and incubation with p-
nitrophenyl phosphate substrate. For each individual mAb, the absorbance values were normalized to the value obtained at pH 7, except for mAb
MG-1A12, where the absorbance values were normalized to the value obtained at pH 4. The bars show mean 6 SEM values from 3 experiments.
doi:10.1371/journal.pone.0030152.g008
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by adding ice-cold 4% formaldehyde in PBS and leaving at RT for
1h. Fixation was then stopped by incubation with 0.1 M glycine
(15 min, RT), followed by 3 washes in PBS. The cells were then
permeabilized with 0.1% Triton X-100 (30 min, RT), blocked
with 2% bovine serum albumin 0.1% Tween-20 (overnight, 4uC),
then incubated with primary mAbs diluted in 2% bovine serum
albumin 0.1% Tween-20 (2h, RT), followed by 3 washes in PBS
0.1% Tween-20. The plates were then incubated with alkaline
phosphatase-conjugated goat anti-mouse IgG1, IgG2a, and IgG2b
pAb (SouthernBiotech) diluted in 2% bovine serum albumin 0.1%
Tween-20 (2h, RT), followed by 6 washes in PBS 0.1% Tween-20.
Bound secondary antibodies were detected by incubation with
SIGMA FAST p-nitrophenyl phosphate substrate (Sigma-Aldrich)
and reading the absorbance at 405nm wavelength on a
Benchmark Microplate Reader (BioRad).
Virion ELISA
MuHV-4 virions (10
5 p.f.u./well) were absorbed to 96-well
MaxiSorp Nunc-Immuno Plates (Thermo Scientific) in PBS
pH 7.4 (overnight, 4uC). After 3 washes in PBS, virions were
treated with phosphate-citrate buffers pH 7, 6, 5, and 4 (15 min,
37uC). The virions were then fixed by adding ice-cold 4%
formaldehyde in PBS and leaving at RT for 1h. Fixation was
stopped by treatment with 0.1 M glycine (15 min, RT), followed
by 3 washes in PBS. The plates were then treated with 0.1%
Triton X-100 (30 min, RT), blocked with 3% bovine serum
albumin (1h, RT), then incubated with primary mAbs diluted in
3% bovine serum albumin (1h, RT), followed by 3 washes in PBS.
The plates were then incubated with alkaline phosphatase-
conjugated goat anti-mouse IgG pAb (Sigma-Aldrich) diluted in
5% normal goat serum (1h, RT), followed by 5 washes in PBS.
Bound secondary antibodies were detected by incubation with
SIGMA FAST p-nitrophenyl phosphate substrate (Sigma-Aldrich)
and reading the absorbance at 405 nm wavelength on a
Benchmark Microplate Reader (BioRad).
Supporting Information
Figure S1 Low magnification images of antigenic
changes in gB and gH. (A) NMuMG cells were left uninfected
or incubated with MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and then
either fixed immediately or first further incubated (1h and 2h, 37uC)
to allow virion endocytosis. The cells were then stained with the gB-
specific mAbs BN-1A7 (IgG2a)a n dM G - 1 A 1 2( I g G 2a), the gH/gL-
specific mAb T2C12 (IgG2a), and the gH-only-specific mAb MG-
9B10 (IgG2a) (green). The cells were counter-stained with DAPI (blue).
(PDF)
Figure S2 Kinetic analysis of gH recognition by the gH/
gL-specific mAb 7E5. (A) NMuMG cells were incubated with
MuHV-4 (3 p.f.u./cell, 2h, 4uC), washed, and then either fixed
immediately or first further incubated (1h and 2h, 37uC) to allow
virion endocytosis. The cells were stained with the gH/gL-specific
IgG2a 7E5 (green), a LAMP-1-specific mAb (red), and DAPI (blue).
(B) Cells were infected and processed as in (A). Infected cells and
uninfected control cells were then incubated with the gH/gL-specific
mAb 7E5 (IgG2a) and bound antibody detected with an alkaline
phosphatase-conjugated secondary antibody and incubation with p-
nitrophenyl phosphate substrate. The bars show mean 6 SEM values
from 6 wells. The experiment shown is representative of two
equivalent experiments. (C) Cells were infected and processed as in
(A), followed by staining with the gH/gL-specific IgG2a 7E5 (green)
and DAPI (blue).
(PDF)
Figure S3 Concanamycin A and NH4Cl treatments and
virus neutralization by SC-9A5 have no effect on
recognition by a pan-gB-specific mAb. Infections, drug
treatments and antibody treatments were as for Figure 3. The cells
were stained with the pan-gB-specific IgG2a MG-4D11 (green), a
LAMP-1-specific mAb (red), and DAPI (blue).
(PDF)
Figure S4 NH4Cl treatment and virus neutralization by
SC-9A5 lead to retention of virions within LAMP-1
+
endosomes for several hours. Infections, drug treatments and
antibody treatments were as for Figure 3.The cells were stained
with the ORF75c-specific IgG1 BN-8C3 (green), a LAMP-1-
specific mAb (red), and DAPI (blue).
(PDF)
Figure S5 Characterization of gp150-specific mAbs. (A)
BHK-21 cells were infected (2 p.f.u./cell, 18h) with wild-type (WT)
or gp150-deficient (M7
-) MuHV-4 or left uninfected (UI). The cells
were then stained with gp150-specific mAbs or with the gN-
specific mAb 3F7 as a control, and analyzed by flow cytometry.
Thus BN-3A4, T1A1 and BH-6H2 were all gp150-specific. (B)
293T cells were transfected with expression plasmids for glycosyl-
phosphatidyl-inositol-linked forms of residues 1-150, 1-250, 1-450
or 301-450 of the full-length 463 amino acid gp150 extracellular
domain. The cells were then stained with gp150-specific mAbs and
analyzed by flow cytometry. Arrows indicate positive staining.
MAbs BN-3A4 and T1A1 also recognized the corresponding
regions of gp150 expressed as GST fusion proteins in E. coli. MAb
BH-6H2 did not, presumably because its recognition is glycan-
dependent (data not shown). (C) Wild-type MuHV-4 virions were
denatured and immunoblotted with anti-gp150 mAbs or with
mAb 3F7 (anti-gN) as a control. The faster migrating bands
detected by BH-6H2 did not appear to be C-terminal gp150
cleavage products as corresponding N-terminal fragments were
not detected in infected cell supernatants (data not shown). Also no
spliced gp150 mRNA was detected in infected BHK-21 cells by
PCR (data not shown). Thus they are likely to be alternative
glycoforms in which the BN-3A4 and T1A1 epitopes are hidden.
(PDF)
Figure S6 The epitope of mAb BN-3A4 on gp150 is lost
pre-fusion. Infections, drug treatments and antibody treatments
were as for Figure 3. The cells were stained with the gp150-specific
Figure 9. The pre-fusion antigenic changes in gB, gH, and gp150 occur independently of each other. (A) NMuMG cells were incubated
with gp150
- MuHV-4 (2h, 4uC), washed, and then either fixed immediately or first further incubated (2h, 37uC) to allow virion endocytosis. Cells were
then stained with the gB-specific mAbs BN-1A7 (IgG2a) and MG-1A12 (IgG2a), the gH/gL-specific mAb T2C12 (IgG2a), and the gH-only-specific mAb
MG-9B10 (IgG2a) (green). The cells were also stained for LAMP-1 (red) and with DAPI (blue). gp150
- virus showed the same gB and gH changes as wild-
type. (B) NMuMG cells were incubated with gL
- MuHV-4 (2h, 4uC), washed, and then either fixed immediately or first further incubated (2h, 37uC) to
allow virion endocytosis. Cells were then stained with the gB-specific mAbs BN-1A7 (IgG2a) and MG-1A12 (IgG2a) and the gp150-specific mAbs T1A1
(IgG2a) and BH-6H2 (IgG2b) (green). The cells were also stained for LAMP-1 (red) and with DAPI (blue). gL
- virions bound to the cell surface displayed
the same gB and gp150 epitopes as wild-type, but were only poorly transported to LAMP-1
+ late endosomes upon incubation at 37uC. Consequently,
gB and gp150 largely remained in their extracellular form.
doi:10.1371/journal.pone.0030152.g009
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(blue).
(PDF)
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